Your browser doesn't support javascript.
loading
Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence.
Johnson, Michael J; Liu, Cuining; Ghosh, Debashis; Lang, Nancy; Levin, Myron J; Weinberg, Adriana.
Afiliação
  • Johnson MJ; University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Liu C; Colorado School of Public Health, Aurora, Colorado, USA.
  • Ghosh D; Colorado School of Public Health, Aurora, Colorado, USA.
  • Lang N; University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Levin MJ; University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Weinberg A; University of Colorado School of Medicine, Aurora, Colorado, USA.
J Infect Dis ; 225(8): 1477-1481, 2022 04 19.
Article em En | MEDLINE | ID: mdl-34850039
ABSTRACT
We compared glycoprotein E (gE)- and varicella zoster virus (VZV)-specific Th1 immunity in 160 adults, aged 50-85 years, randomized to receive live or recombinant zoster vaccine (RZV). gE-specific responses measured by interferon-γ (IFN-γ) and interleukin 2 (IL-2) dual-color Fluorospot were significantly higher at all time points postimmunization in RZV recipients. VZV-specific IL-2+ memory, but not IFN-γ+ or IFN-γ+IL-2+ effector responses, were higher in RZV recipients at ≥3 months postimmunization. Only RZV recipients maintained higher postvaccination gE-specific IL-2+ and IFN-γ+ and VZV-specific IL-2+ responses for 5 years. The 5-year persistence of VZV-specific memory and gE-specific Th1 immunity may underlie superior RZV efficacy. Clinical Trials Registration NCT02114333.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Herpes Zoster / Herpes Zoster Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: J Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Herpes Zoster / Herpes Zoster Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: J Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos